Skip to main content
Erschienen in: Strahlentherapie und Onkologie 2/2012

01.02.2012 | Original article

Dosimetric integration of daily mega-voltage cone-beam CT for image-guided intensity-modulated radiotherapy

verfasst von: PD Dr. A. Zabel-du Bois, S. Nill, S. Ulrich, U. Oelfke, B. Rhein, P. Haering, S. Milker-Zabel, A. Schwahofer

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The goal of this work was to compare different methods of incorporating the additional dose of mega-voltage cone-beam CT (MV-CBCT) for image-guided intensity modulated radiotherapy (IMRT) of different tumor entities.

Material and methods

The absolute dose delivered by the MV-CBCT was calculated and considered by creating a scaled IMRT plan (scIMRT) by renormalizing the clinically approved plan (orgIMRT) so that the sum with the MV-CBCT dose yields the same prescribed dose. In the other case, a newly optimized plan (optIMRT) was generated by including the dose distribution of the MV-CBCT as pre-irradiation. Both plans were compared with the orgIMRT plan and a plan where the last fraction was skipped.

Results

No significant changes were observed regarding the 95% conformity index of the target volume. The mean dose of the organs at risk (OAR) increased by approx. 7% for the scIMRT plan and 5% for the optIMRT plan. A significant increase of the mean dose to the outline contour was observed, ranging from 3.1 ± 1.3% (optIMRT) to 13.0 ± 6.1% (scIMRT) for both methods over all entities. If the dose of daily MV-CBCT would have been ignored, the additional dose accumulated to nearly a whole treatment fraction with a general increase of approx. 10% to the OARs and approx. 4% to the target volume.

Conclusion

Both methods of incorporating the additional MV-CBCT dose into the treatment plan are suitable for clinical practice. The dose distribution of the target volume could be achieved as conformal as with the orgIMRT plan, while only a moderate increase of mean dose to OAR was observed.
Literatur
1.
Zurück zum Zitat Bentel GC, Marks LB, Sherouse GW et al (1995) A customized head and neck support system. Int J Radiat Oncol Biol Phys 32:245–248PubMedCrossRef Bentel GC, Marks LB, Sherouse GW et al (1995) A customized head and neck support system. Int J Radiat Oncol Biol Phys 32:245–248PubMedCrossRef
2.
Zurück zum Zitat Dörr W, Herrmann T (2002) Second primary tumors after radiotherapy for malignancies. Strahlenther Onkol 178:357–362PubMedCrossRef Dörr W, Herrmann T (2002) Second primary tumors after radiotherapy for malignancies. Strahlenther Onkol 178:357–362PubMedCrossRef
3.
Zurück zum Zitat Fiorino C, Reni M, Bolognesi A et al (1998) Set-up error in supine-positioned patients immobilized with two different modalities during conformal radiotherapy of prostate cancer. Radiother Oncol 49:133–141PubMedCrossRef Fiorino C, Reni M, Bolognesi A et al (1998) Set-up error in supine-positioned patients immobilized with two different modalities during conformal radiotherapy of prostate cancer. Radiother Oncol 49:133–141PubMedCrossRef
4.
Zurück zum Zitat Gayou O, Parda DS, Johnson M et al (2007) Patient dose and image quality from mega-voltage cone beam computed tomography imaging. Med Phys 34:499–506PubMedCrossRef Gayou O, Parda DS, Johnson M et al (2007) Patient dose and image quality from mega-voltage cone beam computed tomography imaging. Med Phys 34:499–506PubMedCrossRef
5.
Zurück zum Zitat Guckenberger M, Ok S, Polat B et al (2010) Toxicity after intensity-modulated, image-guided radiotherapy for prostate cancer. Strahlenther Onkol 186:535–543. Erratum in: Strahlenther Onkol 186:705 Guckenberger M, Ok S, Polat B et al (2010) Toxicity after intensity-modulated, image-guided radiotherapy for prostate cancer. Strahlenther Onkol 186:535–543. Erratum in: Strahlenther Onkol 186:705
6.
Zurück zum Zitat Hall EJ, Wuu CS (2003) Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 56:83–88PubMedCrossRef Hall EJ, Wuu CS (2003) Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 56:83–88PubMedCrossRef
7.
Zurück zum Zitat Hermanto U, Frija EK, Lii MJ et al (2007) Intensity modulated radiotherapy (IMRT) and conventional three-dimensional conformal radiotherapy for high grade gliomas: does IMRT increase the integral dose to normal brain? Int J Radiat Oncol Biol Phys 67:1135–1144PubMedCrossRef Hermanto U, Frija EK, Lii MJ et al (2007) Intensity modulated radiotherapy (IMRT) and conventional three-dimensional conformal radiotherapy for high grade gliomas: does IMRT increase the integral dose to normal brain? Int J Radiat Oncol Biol Phys 67:1135–1144PubMedCrossRef
8.
Zurück zum Zitat Hong TS, Tome WA, Chappell RJ et al (2005) The impact of daily setup variations on head-and-neck intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 61:779–788PubMedCrossRef Hong TS, Tome WA, Chappell RJ et al (2005) The impact of daily setup variations on head-and-neck intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 61:779–788PubMedCrossRef
9.
Zurück zum Zitat Kapanen M, Collan J, Saarilahti K et al (2009) Accuracy requirements for head and neck intensity-modulated radiation therapy based on observed dose response of the major salivary glands. Radiother Oncol 93:109–114PubMedCrossRef Kapanen M, Collan J, Saarilahti K et al (2009) Accuracy requirements for head and neck intensity-modulated radiation therapy based on observed dose response of the major salivary glands. Radiother Oncol 93:109–114PubMedCrossRef
10.
Zurück zum Zitat Kry SF, Salehpour M, Followill DS et al (2005) The calculated risk of secondary malignancies from intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 62:1195–1203PubMedCrossRef Kry SF, Salehpour M, Followill DS et al (2005) The calculated risk of secondary malignancies from intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 62:1195–1203PubMedCrossRef
11.
Zurück zum Zitat Miften M, Gayou O, Reitz B et al (2007) IMRT planning and delivery incorporating daily dose from mega-voltage cone-beam computed tomography imaging. Med Phys 34:3760–3767PubMedCrossRef Miften M, Gayou O, Reitz B et al (2007) IMRT planning and delivery incorporating daily dose from mega-voltage cone-beam computed tomography imaging. Med Phys 34:3760–3767PubMedCrossRef
12.
Zurück zum Zitat Milker-Zabel S, Zabel-du Bois A, Huber P et al (2007) Intensity-modulated radiotherapy for complex-shaped meningioma of the skull base: long-term experience of a single institution. Int J Radiat Oncol Biol Phys 68:858–863PubMedCrossRef Milker-Zabel S, Zabel-du Bois A, Huber P et al (2007) Intensity-modulated radiotherapy for complex-shaped meningioma of the skull base: long-term experience of a single institution. Int J Radiat Oncol Biol Phys 68:858–863PubMedCrossRef
13.
Zurück zum Zitat Morin O, Gillis A, Descovich M et al (2007) Patient dose considerations for routine megavoltage cone-beam CT imaging. Med Phys 34:1819–1827PubMedCrossRef Morin O, Gillis A, Descovich M et al (2007) Patient dose considerations for routine megavoltage cone-beam CT imaging. Med Phys 34:1819–1827PubMedCrossRef
14.
Zurück zum Zitat Peng LC, Yang CC, Sim S et al (2006) Dose comparison of megavoltage cone-beam and orthogonal-pair portal images. J Appl Clin Med Phys 8:10–20PubMedCrossRef Peng LC, Yang CC, Sim S et al (2006) Dose comparison of megavoltage cone-beam and orthogonal-pair portal images. J Appl Clin Med Phys 8:10–20PubMedCrossRef
15.
Zurück zum Zitat Peponi E, Glanzmann C, Kunz G et al (2010) Simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) in nasopharyngeal cancer. Strahlenther Onkol 186:135–142PubMedCrossRef Peponi E, Glanzmann C, Kunz G et al (2010) Simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) in nasopharyngeal cancer. Strahlenther Onkol 186:135–142PubMedCrossRef
16.
Zurück zum Zitat Pinkawa M, Holy R, Piroth MD et al (2010) Intensity-modulated radiotherapy for prostate cancer implementing molecular imaging with 18 F-choline PET-CT to define a simultaneous integrated boost. Strahlenther Onkol 186:600–606PubMedCrossRef Pinkawa M, Holy R, Piroth MD et al (2010) Intensity-modulated radiotherapy for prostate cancer implementing molecular imaging with 18 F-choline PET-CT to define a simultaneous integrated boost. Strahlenther Onkol 186:600–606PubMedCrossRef
17.
Zurück zum Zitat Preiser K, Bortfeld T, Hartwig K et al (1998) Inverse radiotherapy planning for intensity modulated photon fields. Radiologe 38:228–234. ReviewPubMedCrossRef Preiser K, Bortfeld T, Hartwig K et al (1998) Inverse radiotherapy planning for intensity modulated photon fields. Radiologe 38:228–234. ReviewPubMedCrossRef
18.
Zurück zum Zitat Radiotherapy equipment – Coordinates, movements and scales. IEC 61217:1996–2008 Radiotherapy equipment – Coordinates, movements and scales. IEC 61217:1996–2008
19.
Zurück zum Zitat Schlegel W, Pastyr O, Bortfeld T et al (1992) Computer systems and mechanical tools for stereotactically guided conformation therapy with linear accelerators. Int J Radiat Oncol Biol Phys 24:781–787PubMedCrossRef Schlegel W, Pastyr O, Bortfeld T et al (1992) Computer systems and mechanical tools for stereotactically guided conformation therapy with linear accelerators. Int J Radiat Oncol Biol Phys 24:781–787PubMedCrossRef
20.
Zurück zum Zitat Stützel J, Oelfke U, Nill S (2008) A quantitive image quality comparison of four different image guided therapy devices. Radiother Oncol 86:20–24PubMedCrossRef Stützel J, Oelfke U, Nill S (2008) A quantitive image quality comparison of four different image guided therapy devices. Radiother Oncol 86:20–24PubMedCrossRef
21.
Zurück zum Zitat Wiezorek T, Schwahofer A, Schubert K (2009) The influence of different IMRT. Techniques on the peripheral dose. Strahlenther Onkol 185:696–702PubMedCrossRef Wiezorek T, Schwahofer A, Schubert K (2009) The influence of different IMRT. Techniques on the peripheral dose. Strahlenther Onkol 185:696–702PubMedCrossRef
22.
Zurück zum Zitat Zabel A, Milker-Zabel S, Huber P et al (2004) Fractionated stereotactic conformal radiotherapy in the management of large chemodectomas of the skull base. Int J Radiat Oncol Biol Phys 58:1445–1450PubMedCrossRef Zabel A, Milker-Zabel S, Huber P et al (2004) Fractionated stereotactic conformal radiotherapy in the management of large chemodectomas of the skull base. Int J Radiat Oncol Biol Phys 58:1445–1450PubMedCrossRef
23.
Zurück zum Zitat Zwicker F, Hauswald H, Nill S, Rhein B et al (2010) New multileaf collimator with a leaf width of 5 mm improves plan quality compared to 10 mm in step-and-shoot IMRT of HNC using integrated boost procedure. Strahlenther Onkol 186:334–343PubMedCrossRef Zwicker F, Hauswald H, Nill S, Rhein B et al (2010) New multileaf collimator with a leaf width of 5 mm improves plan quality compared to 10 mm in step-and-shoot IMRT of HNC using integrated boost procedure. Strahlenther Onkol 186:334–343PubMedCrossRef
Metadaten
Titel
Dosimetric integration of daily mega-voltage cone-beam CT for image-guided intensity-modulated radiotherapy
verfasst von
PD Dr. A. Zabel-du Bois
S. Nill
S. Ulrich
U. Oelfke
B. Rhein
P. Haering
S. Milker-Zabel
A. Schwahofer
Publikationsdatum
01.02.2012
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 2/2012
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-011-0021-z

Weitere Artikel der Ausgabe 2/2012

Strahlentherapie und Onkologie 2/2012 Zur Ausgabe

Mitteilungen der Fachgesellschaften

Adressen, Personalia, Preisausschreibung, Tagungen

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.